New combo therapy aims to ease swallowing in incurable esophageal cancer

NCT ID NCT02297217

Recruiting now Symptom relief Sponsor: AHS Cancer Control Alberta Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial is testing whether adding two chemotherapy drugs (carboplatin and paclitaxel) to standard palliative radiation can better relieve difficulty swallowing in people with incurable esophageal cancer. The study enrolls 50 patients who have trouble swallowing solid foods. The main goal is to see if more patients get lasting improvement in swallowing compared to radiation alone.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Carboplatin and paclitaxel (chemotherapy drugs) plus external beam radiation
What this could lead to: If it works, this combination could provide better relief from difficulty swallowing and improve quality of life for people with incurable esophageal cancer.
What could go wrong: This is a small, early-phase study with only 50 participants. The added chemotherapy may increase side effects without guaranteeing better symptom relief.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESOPHAGEAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

esophageal cancer Esophageal Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ESOPHAGEAL CANCER

Contacts and locations

Locations

Tom Baker Cancer Centre
RECRUITING

Calgary, Alberta, T2N 4N2, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.